Neuro-COVID-19 is more than anosmia: clinical presentation, neurodiagnostics, therapies, and prognosis

Curr Opin Neurol. 2021 Jun 1;34(3):423-431. doi: 10.1097/WCO.0000000000000930.

Abstract

Purpose of review: To provide an overview on current knowledge of neurological symptoms and complications of COVID-19, and to suggest management concepts.

Recent findings: Headache, dizziness, excessive tiredness, myalgia, anosmia/hyposmia, and ageusia/dysgeusia are common nonspecific neurological manifestations during early COVID-19 disease found in the majority of patients. Less frequent but more severe and specific neurological manifestations include Guillain--Barré syndrome, encephalopathy, encephalitis/meningitis, epileptic seizures, and cerebrovascular events. Beyond standard neurological examination, these require a more extensive work-up, including cerebrospinal fluid assessment, neurophysiological evaluation, neuroimaging, and cognitive testing. Symptomatic treatment is advisable unless the neurological complication's immune pathogenesis is proven.

Summary: Neurological manifestations of COVID-19 occur during the acute, para-infectious, and 'recovery' phase. Therapeutic management depends on the clinical presentation and neurological work-up.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anosmia / etiology*
  • Brain Diseases / etiology
  • COVID-19 / complications*
  • Humans
  • Nervous System Diseases / diagnosis
  • Nervous System Diseases / etiology*
  • Nervous System Diseases / therapy*